• Ethics approval granted for two important studies to advance First Responder device
• Studies designed to demonstrate device's fit into emergency workflows and data collection
• $400,000 non-dilutive milestone payment received under Australian Stroke Alliance Project Agreement

EMVision Medical Devices Ltd (ASX:EMV) has provided an update on the progress of its First Responder portable brain scanner program. The company has received ethics approval for two important studies that will advance the First Responder device towards commercial production. The first study is a feasibility, usability and workflow implementation aeromedical study in collaboration with the Royal Flying Doctor Service, South Australia Ambulance Service, and other partners. This study aims to evaluate the First Responder device's usability, reliability, functionality, and workflow metrics to meet user and regulatory requirements. The second study will evaluate the use of the First Responder device during pre-hospital emergency response to acute suspected stroke patients attended by the Melbourne Mobile Stroke Unit, gathering valuable data to inform commercial device development. EMVision has also received a $400,000 non-dilutive milestone payment under its Australian Stroke Alliance Project Agreement, related to the achievement of the First Responder development milestone. The company is progressing the First Responder device towards commercialization via the FDA 510(k) regulatory pathway.

In the coming months, EMVision will be conducting several studies to progress the development of its First Responder device, which will be integral to expediting its commercialization via the FDA 510(k) regulatory pathway.